Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats

@article{Verbeke2014ObeticholicAA,
  title={Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats},
  author={Len Verbeke and Ricard Farr{\'e} and Jonel Trebicka and Mina Komuta and Tania A. Roskams and Sabine Klein and Ingrid Vander Elst and Petra Windmolders and Tim Vanuytsel and Frederik Nevens and Wim Laleman},
  journal={Hepatology},
  year={2014},
  volume={59}
}
The farnesoid X receptor (FXR) is a nuclear bile acid receptor involved in bile acid homeostasis, hepatic and intestinal inflammation, liver fibrosis, and cardiovascular disease. We studied the effect of short‐term treatment with obeticholic acid (INT‐747), a potent selective FXR agonist, on intrahepatic hemodynamic dysfunction and signaling pathways in different rat models of cirrhotic portal hypertension (PHT). For this, thioacetamide (TAA)‐intoxicated and bile‐duct–ligated (BDL) rats were… 
FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
TLDR
Preventative and therapeutic effects of FXR agonist obeticholic acid (OCA) inhibits hepatic inflammation in toxic cirrhotic rats resulting in decreased HSC activation and fibrosis.
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
TLDR
The non-steroidal FXR agonist cilofexor decreased portal hypertension and reduced liver fibrosis in NASH rats and the combination with propranolol additionally reduced mesenteric hyperperfusion.
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor‐dependent inhibition of hepatic stellate cell contraction
TLDR
Investigation of mechanisms underlying DHA protection against chronic CCl4‐caused hepatic fibrosis and portal hypertension demonstrated that DHA attenuated portal hypertension in fibrotic rodents possibly by targeting HSC contraction via a FXR activation‐dependent mechanism.
Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats
TLDR
Long-term administration of palosuran can decrease PP in cirrhosis, which results from decreased hepatic fibrosis and enhanced eNOS-dependent HSC vasodilatation, and in vitro UII/UT mRNA expression increases during HSC activation.
Obeticholic acid, a Farensoid‐X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
TLDR
The observations still supported the conclusion that entecavir reduces hepatic events, and wellcharacterized cohort studies offer valuable insights into the benefits and limitations of antiviral therapy.
Obeticholic acid protects against carbon tetrachloride‐induced acute liver injury and inflammation
TLDR
Results suggest that OCA protects against CCl4‐induced acute liver injury and inflammation, and may be effective antidotes for hepatic inflammation during acute liver Injury.
AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model
TLDR
It is proposed that the relevant mechanisms may be related to the activation of the AMPK/NO pathway in SECs and that this activation promoted NO production in the liver, thereby promoting hepatic sinusoid microcirculation and decreased intrahepatic resistance.
The Status of Bile Acids and Farnesoid X Receptor in Brain and Liver of Rats with Thioacetamide-Induced Acute Liver Failure
TLDR
The results leave open the possibility that mobilization of the BA–FXR axis in the brain may not be necessarily pathognomonic to HE but may depend upon ALF-related confounding factors.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 65 REFERENCES
Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis.
TLDR
Analysis of gene expression in livers from GW4064-treated cholestatic rats revealed decreased expression of bile acid biosynthetic genes and increased expression of genes involved in bile Acid transport, including the phospholipid flippase MDR2.
Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.
TLDR
Findings demonstrate that FXR agonists may be useful for the treatment of non-alcoholic steatohepatitis and reduce inflammatory cell infiltration and hepatic fibrosis in mice fed a methionine and choline-deficient (MCD) diet.
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
TLDR
Treatment with nitroflurbiprofen, an NO-releasing cyclooxygenase inhibitor, improves portal hypertension without major adverse effects in thioacetamide-induced cirrhotic rats by attenuating intrahepatic vascular resistance, endothelial dysfunction, and hepatic hyperreactivity to vasoconstrictors.
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis
TLDR
Reduced intrahepatic endothelial nitric oxide synthase (eNOS) activity contributes to the pathogenesis of portal hypertension (PHT) associated with cirrhosis and in rats with biliary Cirrhosis, an endogenous NOS inhibitor, ADMA, may mediate decreased NOS activity.
Cyclooxygenase‐derived products modulate the increased intrahepatic resistance of cirrhotic rat livers
TLDR
COX‐derived prostanoids, mainly TXA2, play a major role in regulating the response of cirrhotic livers to methoxamine and the mechanisms involved in its regulation are evaluated.
Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
TLDR
Resveratrol administration reduces portal pressure, hepatic stellate cell activation and liver fibrosis, and improves hepatic endothelial dysfunction in cirrhotic rats, suggesting it may be a useful dietary supplement in the treatment of portal hypertension in patients with cirrhosis.
Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
TLDR
It is demonstrated that FXR is a negative modulator of nuclear factor κB (NF‐κB)–mediated hepatic inflammation and may contribute to the critical roles of FXR in hepatoprotection and suppression of hepatocarcinogenesis.
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.
TLDR
It is established that FXR ligands might represent a novel therapeutic option to treat liver fibrosis and that SHP binds JunD and inhibits DNA binding of adaptor protein (AP)-1 induced by thrombin.
Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts.
TLDR
The data suggest that FXR loss significantly reduces fibrosis of the biliary type, but has no impact on non-cholestatic liver fibrosis.
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
TLDR
FXR activation prevents chemically induced intestinal inflammation, with improvement of colitis symptoms, inhibition of epithelial permeability, and reduced goblet cell loss, and the findings provide a rationale to explore FXR agonists as a novel therapeutic strategy for IBD.
...
1
2
3
4
5
...